UK ranked poorly on access to cancer drugs

Research from Sweden has ranked the UK as one of the lowest in the world for its ‘slow and low’ uptake of modern cancer therapies.

The research was carried out by the Karolinska Institute and Stocholm School of Economics and published in the Annals of Oncology.

Worldwide, the US, Austria, France and Switzerland were the found to be the best.

France had the highest five-year survival rate in Europe - 71 per cent in women and 53 per cent in men. These figures were found to be only 53 per cent and 43 per cent in the UK, for women and men respectively.

Lead researcher Dr Begt Jonsson said: 'It is our hope that this report will inspire policy-makers to take action to address these imbalances so that access to new innovative cancer drugs does not become dependent on the patient's country of residence.'

What do you think? Comment below or email us healthcare.republic@haymarket.com

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in